Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,842,683 entitled, "Neurotherapeutic Compositions and Methods."
“This new patent coverage for cognition enhancement using beta-lactam compounds further broadens our CNS-related portfolio and strengthens our intellectual property position with potential treatments for neurodegeneration.”
The patent covers a method of enhancing cognitive function and treating cognitive disorders such as dementia, amnesia or Altzheimer's disease, using beta-lactam compounds. The patent also covers the combination with one or more other enzyme inhibitors, for example effective amounts of a beta-lactamase inhibitor, or another NAALADase inhibitor, or a P-glycoprotein efflux inhibitor, to enhance brain levels of the active compound.
Rick Soni, President of Rexahn, noted, "This new patent coverage for cognition enhancement using beta-lactam compounds further broadens our CNS-related portfolio and strengthens our intellectual property position with potential treatments for neurodegeneration."
Imlunestrant offers new hope for ER-positive HER2-negative breast cancer